JP2000508659A - 心血管疾患関連の危険性を低減する組み合わせ療法 - Google Patents

心血管疾患関連の危険性を低減する組み合わせ療法

Info

Publication number
JP2000508659A
JP2000508659A JP9537264A JP53726497A JP2000508659A JP 2000508659 A JP2000508659 A JP 2000508659A JP 9537264 A JP9537264 A JP 9537264A JP 53726497 A JP53726497 A JP 53726497A JP 2000508659 A JP2000508659 A JP 2000508659A
Authority
JP
Japan
Prior art keywords
hmg
inhibitor
pharmaceutically acceptable
vitamin
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9537264A
Other languages
English (en)
Japanese (ja)
Inventor
トバート，ジヨナサン・エイ
Original Assignee
メルク エンド カンパニー インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9612082.9A external-priority patent/GB9612082D0/en
Priority claimed from GBGB9616804.2A external-priority patent/GB9616804D0/en
Application filed by メルク エンド カンパニー インコーポレーテッド filed Critical メルク エンド カンパニー インコーポレーテッド
Publication of JP2000508659A publication Critical patent/JP2000508659A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
JP9537264A 1996-04-17 1997-04-14 心血管疾患関連の危険性を低減する組み合わせ療法 Ceased JP2000508659A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US1568996P 1996-04-17 1996-04-17
GBGB9612082.9A GB9612082D0 (en) 1996-06-10 1996-06-10 Combination therapy for reducing the risks associated with cardiovascular disease
US2097796P 1996-06-24 1996-06-24
GB60/015,689 1996-08-09
GBGB9616804.2A GB9616804D0 (en) 1996-08-09 1996-08-09 Combination therapy for reducing the risks associated with cardiovascular disease
GB9616804.2 1996-08-09
GB60/020,977 1996-08-09
GB9612082.9 1996-08-09
PCT/US1997/006127 WO1997038694A1 (en) 1996-04-17 1997-04-14 Combination therapy for reducing the risks associated with cardiovascular disease

Publications (1)

Publication Number Publication Date
JP2000508659A true JP2000508659A (ja) 2000-07-11

Family

ID=27451457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9537264A Ceased JP2000508659A (ja) 1996-04-17 1997-04-14 心血管疾患関連の危険性を低減する組み合わせ療法

Country Status (5)

Country Link
EP (1) EP0904082A4 (de)
JP (1) JP2000508659A (de)
AU (1) AU732465B2 (de)
CA (1) CA2251972A1 (de)
WO (1) WO1997038694A1 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004115500A (ja) * 2002-08-02 2004-04-15 Sankyo Co Ltd ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
JP2004189716A (ja) * 2002-07-11 2004-07-08 Sankyo Co Ltd 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
JP2005538104A (ja) * 2002-07-26 2005-12-15 メルク　シャープ　エンド　ドーム　リミテッド コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物
JP2008088184A (ja) * 2001-01-26 2008-04-17 Schering Corp ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
WO2015012338A1 (ja) * 2013-07-26 2015-01-29 学校法人 久留米大学 動脈硬化の治療または予防のためのアスピリンおよび葉酸の併用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6274603B1 (en) 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
JP2003524582A (ja) * 1997-12-12 2003-08-19 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗高脂血症性スタチン−Ｌｐ（ａ）阻害剤配合物
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
AU4671101A (en) * 2000-04-10 2001-10-23 Malcolm R. Law Formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
TWI275389B (en) * 2000-10-23 2007-03-11 Sankyo Company, Limited blood
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
CN1240379C (zh) 2000-11-07 2006-02-08 三共株式会社 过氧化脂质降低剂组合物
CA2427618A1 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
WO2002047683A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides dans le sang
US7037934B2 (en) 2000-12-14 2006-05-02 Sankyo Company, Limited Blood lipid ameliorant composition
WO2002047682A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides sanguins
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
TW200409635A (en) * 2002-08-02 2004-06-16 Sankyo Co A pharmaceutical composition containing a HMG-CoA reductase
EP1703911A4 (de) * 2003-12-23 2009-03-18 Medicure Int Inc Kombinationstherapien unter verwendung einer zusammensetzung mit einem hmg-coa-reduktase-inhibitor und einer vitamin b6-verwandten verbindung
PE20051166A1 (es) * 2004-03-29 2006-02-13 Wyeth Corp Suplementos nutricionales multivitaminicos y minerales
AU2006204563A1 (en) * 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
CA2664421A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Hmg coa reductase mediated modulation of neurogenesis
EP2810644A1 (de) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895107A (en) * 1970-04-15 1975-07-15 Morrison L M CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
DE4326698C2 (de) * 1993-08-09 1997-05-28 Puetter Medice Chem Pharm Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Prophylaxe und Therapie von Arteriosklerose
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008088184A (ja) * 2001-01-26 2008-04-17 Schering Corp ペルオキシソーム増殖因子活性化レセプター（ｐｐａｒ）活性化剤およびステロール吸収阻害剤の組合せおよび血管症状の処置
JP2004189716A (ja) * 2002-07-11 2004-07-08 Sankyo Co Ltd 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
JP2005538104A (ja) * 2002-07-26 2005-12-15 メルク　シャープ　エンド　ドーム　リミテッド コレステロール吸収阻害剤、ＨＭＧ−ＣｏＡレダクターゼ阻害剤および安定化剤を含有する組成物
US7718643B2 (en) 2002-07-26 2010-05-18 Schering Corporation Pharmaceutical formulation
JP2004115500A (ja) * 2002-08-02 2004-04-15 Sankyo Co Ltd ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
WO2015012338A1 (ja) * 2013-07-26 2015-01-29 学校法人 久留米大学 動脈硬化の治療または予防のためのアスピリンおよび葉酸の併用

Also Published As

Publication number Publication date
EP0904082A4 (de) 2001-09-26
EP0904082A1 (de) 1999-03-31
AU2666597A (en) 1997-11-07
WO1997038694A1 (en) 1997-10-23
AU732465B2 (en) 2001-04-26
CA2251972A1 (en) 1997-10-23

Similar Documents

Publication Publication Date Title
JP2000508659A (ja) 心血管疾患関連の危険性を低減する組み合わせ療法
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP4711600B2 (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
ES2274013T3 (es) Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
US6180660B1 (en) Cholesterol-lowering therapy
CN101217952A (zh) 用于预防心血管事件发病的组合物
EA008888B1 (ru) Композиции, включающие ингибитор абсорбции холестерина, ингибитор hmg-coa-редуктазы и стабилизирующий агент
US20060223811A1 (en) Triglycerine depressant composition
ES2238982T3 (es) Formulacion de carbamazepina de liberacion prolongada.
ZA200103918B (en) Combination of cerivastatin and fibrates.
AU1361299A (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
JPH0140009B2 (de)
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
WO2001045698A1 (en) Combination therapy for treating neurodegenerative disease
CA2534910C (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
US20070092567A1 (en) Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
IL133492A (en) Pharmaceutical preparations containing alkanol L - carnitine in combination with a statin for the treatment of diseases caused by a change in lipid metabolism
US6998422B2 (en) Lipid peroxide-lowering compositions
JP4928256B2 (ja) 肥満を治療するための、フィブラート系薬剤及びオルリスタットの使用
WO1998001119A2 (en) Pharmaceutical compositions comprising simvastatin
CN100566716C (zh) 治疗高血脂症的组合物
WO2001085155A1 (fr) Procede et compositions pour l'inhibition de l'arteriosclerose
US20070053930A1 (en) Combination therapy for treatment of high cholesterol
BR102013028912A2 (pt) composição farmacêutica, forma farmacêutica oral, cápsula, comprimido de dupla camada, usos, método de tratamento de hipercolesterolemia, hipertrigliceridemia e/ou dislipidemia mista e método de prevenção de aterosclerose, diabetes ou prevenção secundária de outras doenças cardiovasculares
CN100358526C (zh) 治疗高血脂症的组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080121

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080617